Precision BioSciences, Inc.
302 East Pettigrew Street
About Precision BioSciences, Inc.
Precision BioSciences, Inc. (Nasdaq: DTIL) is a clinical stage gene editing company developing in vivo gene editing and ex vivo allogeneic CAR T therapies with its highly precise and versatile ARCUS genome editing platform. ARCUS uses sequence-specific DNA-cutting enzymes, or nucleases designed for gene knock out, as well as highly sophisticated edits for gene insertion and/or gene repair. Precision’s in vivo gene editing pipeline consists of wholly-owned preclinical candidates for primary hyperoxaluria type 1 (PBGENE-PH1), familial hypercholesteremia (PBGENE-PCSK9) and chronic hepatitis B (PBGENE-HBV). It has also partnered with Lilly to develop candidates for Duchenne muscular dystrophy and two other programs targeting the liver and CNS. Precision’s allogeneic CAR T pipeline consists of multiple investigational candidates in early-stage clinical trials, including its first and second generation CD19 targeting candidates PBCAR0191 and PBCAR19B for relapsed and/or refractory (R/R) non-Hodgkin and B-cell lymphoma patients. Precision has also prioritized development of PBCAR269A, its BCMA targeted candidate in combination with a gamma secretase inhibitor for R/R patients with multiple myeloma. Precision BioSciences and its in-house manufacturing facility for AAV, mRNA, and CAR T cells is based in Durham, North Carolina. For more information about Precision BioSciences please visit www.precisionbiosciences.com
Stock Symbol: DTIL
Stock Exchange: NASDAQ
Precision BioSciences: Culture
227 articles about Precision BioSciences, Inc.
Precision BioSciences Announces Appointment Of Gene Liau, Ph.D. And Bruce Mccreedy, Ph.D. To Management Team
Danziger Innovations And Precision BioSciences Announce Successful Genome Modification Collaboration In Ornamental Plants
Precision BioSciences And Agrivida, Inc. Announce Collaborative Trait Development Agreement And Successful Genetic Modification
Precision BioSciences Announces First Publication of Targeted Knockout Rats Using Engineered Meganuclease Technology
Precision BioSciences Announces Publication of Cotton Trait Stacking Success in Collaboration With Bayer CropScience AG
Precision BioSciences Announces Allowance of Eleventh U.S. Patent Application Related to Genome Editing Nucleases
Precision BioSciences Files Tenth Patent Infringement Lawsuit Against CELLECTIS SA Related to Meganuclease Technology and Requests Permanent Injunction
Precision BioSciences Files Ninth Patent Infringement Lawsuit Against CELLECTIS SA Related to Engineered Meganucleases
Precision BioSciences Files Seventh and Eighth Patent Infringement Lawsuits Against CELLECTIS SA, Seeks Permanent Injunction and Monetary Damages
Precision BioSciences Announces Sixth Patent Infringement Lawsuit Against CELLECTIS SA, Seeks Permanent Injunction Against Importation Into U.S.
Precision BioSciences Files Fifth Patent Infringement Lawsuit Against CELLECTIS SA Related to Engineered Meganucleases
Precision BioSciences Announces Allowance of Five Additional U.S. Patent Applications Related to Engineered Meganucleases
Precision BioSciences Files Two New Infringement Lawsuits Against CELLECTIS SA, Requests Permanent Injunction Against Importation of Infringing Materials into U.S.
Precision BioSciences Receives Notice of Intent to Grant for New European Patent Covering Engineered Meganucleases